CXCL1 and Patent ductus arteriosus: RIPK3 was found highly expressed in pancreatic ductal adenocarcinoma (PDA), deletion of RIPK3 protects against oncogenic progression of PDA, which partially depends on necroptosis-induced expression of CXCL1 that promotes macrophage-induced adaptive immune suppression [120].